Piper Sandler Maintains Overweight on Edwards Lifesciences (EW) Ahead of PARTNER 3 7-Year Results

Edwards Lifesciences Corporation (NYSE:EW) ranks among the best medical device stocks to invest in. Piper Sandler maintained its Overweight rating and $90 price target for Edwards Lifesciences Corporation (NYSE:EW) on October 7, ahead of the expected 7-year findings from Edwards’ PARTNER 3 study, which is set to be presented on October 27 at the Transcatheter Cardiovascular Therapeutics (TCT) conference.

With follow-up spanning ten years, Edwards’ historic PARTNER 3 trial compares surgical aortic valve replacement (SAVR) with its Sapien 3 transcatheter aortic valve replacement (TAVR) in low-risk patients.

According to Piper Sandler, upcoming data will likely show that TAVR is not inferior to SAVR on these endpoints, which could render the findings a “non-event with minimal commercial implications.”

Edwards Lifesciences Corporation (NYSE:EW) develops and sells patient-focused medical innovations, including transcatheter heart valves and hemodynamic monitoring systems for the treatment of structural heart disease and critical care.

While we acknowledge the potential of EW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.